Supplementary material to article by H-H. Wang et al. "Efficacy of Rituximab for Pemphigus: A Systematic Review and Meta-analysis of Different Regimens"

Table SIV. Linear regression and logistic regression of outcomes

	Time to disease control	TCRon	Complete remission duration	Complete remission	Relapse
Risk factor	β coefficient (95% CI)	β coefficient (95% CI)	β coefficient (95% CI)	OR (95% CI)	OR (95% CI)
Constant	2.300	4.297	-3.530	7.345	0.601
Age, years	-0.01 (-0.02-0.01)	-0.02 (-0.06-0.01)	0.02 (-0.11-0.15)	1.00 (0.97-1.03)	0.98 (0.95-1.02)
Sex (male)	-0.03(-0.35-0.29)	0.69 (-0.26-1.65)	-0.93 (-5.44-3.58)	0.77 (0.30-1.98)	1.46 (0.59–3.59)
Type (PF vs. PV)	-0.21(-0.61-0.19)	0.71 (-0.49-1.91)	-0.12 (-2.58-2.34)	1.14 (0.34–3.88)	0.55 (0.17–1.71)
Disease severity ^a	0.13(-0.21-0.46)	-0.58 (-1.70-0.53)	-2.61 (-4.89-0.34)	0.99 (0.37–2.65)	0.54 (0.20–1.47)
Disease duration	0.01(-0.04-0.06)	-0.15 (-0.32-0.01)	-0.63 (-1.29-0.01)	0.90 (0.80-0.97)*	0.99 (0.34-2.92)
Protocol (high vs. low)	-0.02(-0.43-0.39)	0.78 (-0.38-1.95)	2.57(1.19-4.95)*	0.99 (0.27–3.54)	0.87 (0.74–1.02)
Follow-up time	Not applicable	Not applicable	0.47 (0.59-0.64)*	Not applicable	1.11 (1.02-1.20)*

^aSevere vs. mild/moderate.

Full-adjusted model included age, gender, type of pemphigus, disease duration, disease severity, treatment protocols and follow-up time.

Based on the raw data of 213 patients from 17 separate studies (4–10, 12, 13, 16, 17, 21, 23, 24, 31, 35, 36).

Values expressed as odds ratio (OR) (95% confidence interval; 95% CI).

^{*}p<0.05 with significant difference.

PV: pemphigus vulgaris; PF: pemphigus foliaceus; TCRon: time to complete remission on therapy.